Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are frontline therapies in treating cardiovascular disorders including hypertension and diabetes; however, they may upregulate ACE2 expression in some animal models1,3,4. Here, ACE2 is linked to cardiovascular disorder.